Skip to main content
| News

Evolva brings natural sugar blocker to market

21.01.2021

The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be used both for healthy eating and as a reducing sugar in food processing.

Research and development in a laboratory of Evolva (img: Evolva)

Evolva, a biotech company headquartered in Reinach in the canton of Basel-Landschaft, has presented its new product L-arabinose, a natural sugar blocker. According to a press release, studies have demonstrated the effect of L-arabinose on adjusting to a healthy blood sugar level. The sugar blocker can also help with maintaining a healthy weight, for example by foregoing food and drink that contains a lot of sugar. L-arabinose is created by fermentation and is a good substitute for sugar in products such as yogurt, chocolate, soft drinks, ice cream, cereals, energy bars, and confectionary. The company’s press release states that its effect as a reducing sugar means that it can be used to create salty and savory chicken and beef flavors.

Oliver Walker, CEO of Evolva, is quoted as saying: “As people around the world continue to strive to live a healthier lifestyle, we are committed to helping our customers create healthier, more sustainable solutions. With this launch we are confirming our ability to deliver innovations that support human health and wellbeing.”

This new, natural sugar blocker is also of economic interest. Evolva has a current market volume of 250 million Swiss francs, and market growth of around 5 percent per year is anticipated. Evolva has revealed that marketing discussions are already underway with major clients.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel to become Europe’s Silicon Valley of biotech

Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....

Read More
1 2 3 63

Do you have a question? We'd like to hear from you.